Relief Therap 
Welcome,         Profile    Billing    Logout  
 3 Products   36 Diseases   3 Products   4 Trials   668 News 


123456»
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    The impact of aviptadil as an add-on to the standard of care in acute respiratory distress syndrome (PS-5; Poster board no. 10) -  May 31, 2024 - Abstract #ERS2024ERS_2054;    
    This research underscores the potential of aviptadil as an adjunct treatment in ARDS management, showing notable improvements in oxygenation and a trend toward enhanced survival. Further, larger studies are needed.
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Inhaled Aviptadil is a new hope for recovery of lung damage due to COVID-19 (PS-26; Poster board no. 2) -  May 31, 2024 - Abstract #ERS2024ERS_1609;    
    Further, larger studies are needed. Inhaled Aviptadil could be a way to treat and fasten the recovery of lungs from COVID-19.
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Exploring the Consequences: Severity and Mortality of Hemorrhagic ARDS in Leptospirosis (PS-5; Poster board no. 8) -  May 31, 2024 - Abstract #ERS2024ERS_355;    
    Early diagnosis is crucial in management of hemorrhagic ARDS in Leptospirosis, which has a significant mortality in Intensive Care settings. Aviptadil does not affect overall mortality, but it significantly improves survival in more severe patients (according to SOFA score), with an increase in the duration of admission.
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS (clinicaltrials.gov) -  Jan 17, 2024   
    P2,  N=83, Terminated, 
    N=132 --> 83 | Trial completion date: Dec 2023 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Jun 2023; Difficulties recruiting participants for the Aviptadil study as there are nowadays very few hospitalized COVID patients. Continuous screening has been carried out but none of the patients met the eligibility criteria for the study.
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Journal:  Peptiligase, an enzyme for efficient chemo-enzymatic synthesis of aviptadil. (Pubmed Central) -  Nov 27, 2023   
    The overall time of ligation is shorter than those peptides with similar lengths and hinderance to aviptadil which reported for conventional synthesis by full solid-phase peptide synthesis. Yields ranged from 54?% to 76?%.
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Trial completion:  HOPE: A Clinical Study Evaluating Inhaled Aviptadil on COVID-19 (clinicaltrials.gov) -  Jun 5, 2023   
    P2,  N=80, Completed, 
    The smaller than planned sample size for the remdesivir trial did not permit definitive conclusions regarding safety or efficacy. Recruiting --> Completed
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    AVIPTADIL (Twitter) -  Apr 24, 2023   
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Potential Value of the Radiographic Assessment of Lung Edema (RALE) Score to Assess Resolution of Pulmonary Edema in a Clinical Trial in ARDS (Walter E. Washington Convention Center, Area K, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_4968;    
    In a trial of Aviptadil for treatment of COVID-19 respiratory failure, treatment with Aviptadil was associated with significant improvement in RALE score at Day 3 versus placebo. In the context of the observed improvement in 60-day survival and PaO2/FiO2 ratio over 7 days in the parent trial, these findings support the utility of RALE as a clinical trial outcome measure to assess resolution of pulmonary edema.
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
    #Aviptadil ....find the story (Twitter) -  Feb 11, 2023   
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Enrollment change, Trial completion date, Trial primary completion date:  Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS (clinicaltrials.gov) -  Feb 8, 2023   
    P2,  N=132, Recruiting, 
    In the context of the observed improvement in 60-day survival and PaO2/FiO2 ratio over 7 days in the parent trial, these findings support the utility of RALE as a clinical trial outcome measure to assess resolution of pulmonary edema. N=82 --> 132 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
    Trial termination:  AVINALI: Inhaled ZYESAMI (clinicaltrials.gov) -  Feb 3, 2023   
    P2/3,  N=144, Terminated, 
    N=82 --> 132 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Nov 2023 Recruiting --> Terminated; Sponsor decision
  • ||||||||||  Zyesami IV (aviptadil intravenous) / Relief Therap, NRx Pharma
    Trial completion, Trial completion date, Trial primary completion date:  TESICO: ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (clinicaltrials.gov) -  Dec 19, 2022   
    P3,  N=473, Completed, 
    Recruiting --> Terminated; Sponsor decision Active, not recruiting --> Completed | Trial completion date: Apr 2023 --> Nov 2022 | Trial primary completion date: Nov 2022 --> Aug 2022
  • ||||||||||  Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
    Have you heard of #Aviptadil ? (Twitter) -  Dec 1, 2022   
  • ||||||||||  Trial completion date, Trial primary completion date:  I-SPY_COVID: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (clinicaltrials.gov) -  Oct 10, 2022   
    P2,  N=1500, Recruiting, 
    Given the absence of drug-related serious adverse events and acceptable safety profile, we believe the benefit versus risk for the use of Aviptadil is favorable for patient treatment. Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Jul 2022 --> Jul 2023